KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Deffered Revenue: 2017-2023

Historic Non-Current Deffered Revenue for BeOne Medicines (ONC) over the last 4 years, with Dec 2023 value amounting to $300,000.

  • BeOne Medicines' Non-Current Deffered Revenue fell 99.29% to $300,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $300,000, marking a year-over-year decrease of 99.29%. This contributed to the annual value of $300,000 for FY2023, which is 99.29% down from last year.
  • Per BeOne Medicines' latest filing, its Non-Current Deffered Revenue stood at $300,000 for Q4 2023, which was down 0.00% from $300,000 recorded in Q3 2023.
  • In the past 5 years, BeOne Medicines' Non-Current Deffered Revenue registered a high of $220.3 million during Q4 2021, and its lowest value of $300,000 during Q3 2023.
  • For the 3-year period, BeOne Medicines' Non-Current Deffered Revenue averaged around $87.7 million, with its median value being $63.8 million (2021).
  • Per our database at Business Quant, BeOne Medicines' Non-Current Deffered Revenue skyrocketed by 186.77% in 2022 and then slumped by 99.80% in 2023.
  • Over the past 4 years, BeOne Medicines' Non-Current Deffered Revenue (Quarterly) stood at $8.2 million in 2019, then reached $220.3 million in 2021, then slumped by 80.92% to $42.0 million in 2022, then tumbled by 99.29% to $300,000 in 2023.
  • Its Non-Current Deffered Revenue stands at $300,000 for Q4 2023, versus $300,000 for Q3 2023 and $24.3 million for Q2 2023.